Neurology>Dementia

Dementia at Young Ages More Common Than Previously Thought

— Alzheimer’s most prevalent form of young-onset dementia

by Judy George, Senior Staff Writer, MedPage Today July 19, 2021

https://www.medpagetoday.com/neurology/dementia/93626

A computer rendering of a brain dissolving. Une image contenant texte

Description générée automatiquement

Young-onset dementia — dementia before age 65 — may be more prevalent than previously thought, a systematic review and meta-analysis showed.

Based on 74 studies of nearly 2.8 million people, the global age-standardized prevalence of young-onset dementia was 119.0 per 100,000, corresponding to 3.9 million people ages 30 to 64, reported Sebastian Köhler, PhD, of Maastricht University in The Netherlands, and co-authors in JAMA Neurology.

This prevalence is higher than estimates from the two most referenced reports, both retrospective register-based studies, that showed a prevalence of 54.0 and 42.3 per 100,000 population, the researchers noted.

“Although this is higher than previously thought, it is probably an underestimation owing to lack of high-quality data,” Köhler and colleagues wrote.

Age-standardized prevalence was similar in women and men, highest in upper-middle-income countries, and highest for Alzheimer’s disease, followed by vascular dementia and frontotemporal dementia.

“At one time in the not-too-distant past, young-onset dementia was considered a disease, whereas later-onset dementia was considered the inevitable consequence of aging,” observed David Knopman, MD, of the Mayo Clinic in Rochester, Minnesota, in an accompanying editorial.

“We now reject such a formulation, but within that misguided dichotomy is a recognition of the dramatic differences in prevalence and incidence of young-onset dementia compared with later-onset dementia.”

“Young-onset dementia is a particularly disheartening diagnosis because it affects individuals in their prime years, in the midst of their careers, and while raising families,” Knopman added.

“Most dementia care is geared for older patients, and as a consequence, services are rarely available to address the needs of someone diagnosed with dementia in their 50s who has dependent children at home and a spouse who must continue working.”

In their study, Köhler and co-authors examined 95 studies published from January 1990 through March 2020 in a systematic review and included 74 of these studies, spanning 2,760,379 unique patients, in a meta-analysis.

They estimated age-specific prevalence in 5-year bands from ages 30 to 64.

Because pooling would apply the same weight to each age group, the researchers standardized results by the WHO world standard population of 2000 to 2025, the U.S. standard population of 2000, and the European standard population of 2011 to 2020.

Overall, register-based studies reported lower prevalence estimates than cohort studies.

Estimates in low-income countries and younger age ranges were scarce.

Age-standardized prevalence estimates per 100,000 population were 159.4 in Europe and 114.7 in the U.S., due mainly to differences in population ages.

This corresponded to 500,000 people in Europe and 200,000 in the U.S. with young-onset dementia.

Estimates per 100,000 ranged from 1.1 in people ages 30 to 34 to 77.4 in people ages 60 to 64. Overall, young-onset Alzheimer’s disease had the highest prevalence, at 41.1 per 100,000. However, until age 50, Alzheimer’s had a lower prevalence than vascular dementia and frontotemporal dementia.

“The diminishing prevalence of dementia at younger ages means that epidemiological case finding almost always relies on passive surveillance methods,” Knopman noted.

“The acknowledged disadvantage of passive surveillance for dementia is the lack of control of diagnostic methods across numerous clinicians, raising the possibility of undercounting or overcounting cases owing to misdiagnosis (e.g., young-onset dementia as a psychiatric disorder or vice versa) or of noncontact by the young patient with dementia with the medical system,” he pointed out.

“Milder cases are almost certainly likely to be undercounted; therefore, prevalence estimates in the meta-analysis could be higher if the full spectrum of symptomatic cognitive impairment was recognized.”

The analysis had several limitations, Köhler and co-authors acknowledged. Studies from Africa and low-income countries were underrepresented.

In addition, 41 studies reported only on people ages 60 to 64. Some studies had small samples.

At times, dementia diagnosis was either defined poorly or not reported properly.

“To yield more accurate and comparable prevalence estimates in the future, efforts should be made to conduct more cohort studies and to standardize procedures and reporting of prevalence studies,” the researchers wrote.

Judy George covers neurology and neuroscience news for MedPage Today, writing about brain aging, Alzheimer’s, dementia, MS, rare diseases, epilepsy, autism, headache, stroke, Parkinson’s, ALS, concussion, CTE, sleep, pain, and more. Follow 

Disclosures

This study was supported by the Gieskes-Strijbis Foundation, Alzheimer Netherlands, and the Dutch Young-Onset Dementia Knowledge Center.

Researchers reported relationships with ZonMw, NWO, CVON, Combinostics, Fujifilm, Roche, AVID, Health-Holland, Topsector Life Sciences & Health, EU Joint Programme-Neurodegenerative Disease Research, Stichting Dioraphte, Stichting Equilibrio, Pasman Stichting, Biogen, Life-MI, Philips, Novartis NL, Neurocast, ADX-Neuroscience, Boehringer Ingelheim, Danone, Eisai, WebMD, Oxford Health Policy Forum CIC, Australian National Health and Medical Research Council, Ministry of Health Singapore, and Temasek Foundation.

Knopman reported serving on a data safety monitoring board for the Dominantly Inherited Alzheimer Network study; serving on a data safety monitoring board for a tau therapeutic for Biogen but receiving no personal compensation; serving as an investigator in clinical trials sponsored by Biogen, Lilly Pharmaceuticals, and the University of Southern California; consulting for Hoffman-LaRoche, Samus Therapeutics, Third Rock, and Alzeca Biosciences but receiving no personal compensation; and receiving grants from NIH.

Primary Source – JAMA Neurology

Source Reference: Hendriks S, et al “Global prevalence of young-onset dementia: a systematic review and meta-analysis” JAMA Neurol 2021; DOI: 10.1001/jamaneurol.2021.2161.

Secondary Source – JAMA Neurology

Source Reference: Knopman DS “Young-onset dementia — new insights for an underappreciated problem” JAMA Neurol 2021; DOI: 10.1001/jamaneurol.2021.1760.